Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ferritin heavy chain CRISPR Activation Plasmid (h): sc-418152-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ferritin heavy chain CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- ferritin heavy chain CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by ferritin heavy chain CRISPR Activation Plasmid (h) and ferritin heavy chain CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the FTH1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ferritin heavy chain Antibody (B-12): sc-376594
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ferritin heavy chain CRISPR Activation Plasmid (h) | sc-418152-ACT | 20 µg | $397.00 | |||
ferritin heavy chain CRISPR Activation Plasmid (h2) | sc-418152-ACT-2 | 20 µg | $397.00 |
FTH1 encodes ferritin heavy chain, a ferroxidase subunit of the ferritin complex that converts Fe2+ to Fe3+ and enables iron storage, thereby limiting labile iron and iron-catalyzed oxidative damage. By buffering intracellular iron, FTH1 influences redox homeostasis, mitochondrial metabolism, and the iron-responsive element/iron regulatory protein (IRE/IRP) network that coordinates iron uptake, utilization, and storage. Ferritin heavy chain also intersects with stress-response programs and iron-dependent cell death pathways such as ferroptosis through its control of iron availability. Dysregulated FTH1 expression or ferritin function is associated with altered oxidative stress responses and iron mismanagement observed across cancer biology, neurodegeneration, and inflammatory conditions.
ferritin heavy chain CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FTH1 expression without altering the underlying DNA sequence.
ferritin heavy chain CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FTH1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FTH1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous ferritin heavy chain expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FTH1 locus and enabling the study of ferritin heavy chain-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of ferritin heavy chain pathway restoration in tumor cells with silenced or reduced FTH1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.